A Phase II Trial Of The JAK-Inhibitor Ruxolitinib (INCB018424) In Combination With Exemestane For Patients With Estrogen Receptor (ER) Positive Advanced Breast Cancer)

Trial Profile

A Phase II Trial Of The JAK-Inhibitor Ruxolitinib (INCB018424) In Combination With Exemestane For Patients With Estrogen Receptor (ER) Positive Advanced Breast Cancer)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs Ruxolitinib (Primary) ; Exemestane
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms JAKEE
  • Most Recent Events

    • 23 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 13 Jan 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Oct 2017 as reported by ClinicalTrials.gov.
    • 22 Apr 2015 Interim results (n=15) presented at the 106th Annual Meeting of the American Association for Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top